A similar skewed ratio has recently been reported with an agonist anti-OX40 mAb, as well as antagonist anti-CTLA4 mAb, suggesting that an altered intra-tumor Teff:Treg ratio may be predictive of anti-tumor activity of these immune-modulating approaches[22], [23], [30], [31]. This evidence concerns the gene TNFRSF4 and neoplasm.